drugset / Trial / NCT04643249
Drug-drug Interaction Study of KL1333 in Healthy Subjects
NaCrossoverOpen-labelTreatment
Summary
A Phase I, Open-label, Fixed-sequence, Crossover, Drug-drug Interaction Study to Investigate the Inhibition Potential of KL1333 on CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 in Healthy Subjects
Timeline
- Start
- 2020-11-10
- Primary completion
- 2020-12-17
- Completion
- 2020-12-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bupropion | Small molecule | — | — |
| Subject | Caffeine | Small molecule | — | — |
| Subject | Dextromethorphan | Unknown | — | — |
| Subject | Flurbiprofen | Small molecule | — | — |
| Subject | Midazolam | Small molecule | — | — |
| Subject | Napazimone | Small molecule | — | — |
| Subject | Omeprazole | Other / unclassified | — | — |
| Subject | Repaglinide | Small molecule | — | — |